Clinical Trial Update: Placebo Versus SBR759 in Lowering Phosphate in Dialysis Patients [Phase 3]

View source ↗

Summary

Phase 3 trial comparing placebo to SBR759 for lowering phosphate in dialysis patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperphosphatemia

Drugs mentioned

• SBR759

Snippet

Sponsor: Novartis | Conditions: Hyperphosphatemia, Chronic Kidney Disease | Phase 3 | Status: COMPLETED